DOI:
10.1055/s-00000077
Seminars in Thrombosis and Hemostasis
LinksClose Window
References
Craig T, Magerl M, Levy DS. et al.
Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet 2022;
399 (10328): 945-955
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.